MedTrace Logo

Strain Imaging in Breast Cancer Patients Receiving Trastuzumab

NCT02080390 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2019-03-01

No results posted yet for this study

Summary

The purpose of this research study is to evaluate the effects of the chemotherapeutic drug, Trastuzumab (Herceptin) on the heart. Trastuzumab (Herceptin) is used to treat specific types of breast cancer and is known to cause weakening of the heart. Unfortunately, little is know as to why this this happens. The investigators want to identify any factors that may lead to the early detection, treatment and prevention of the cardiotoxicity (heart problem) associated with this drug.

Conditions

  • Her 2 Positive Breast Cancer

Interventions

PROCEDURE

Transthoracic echocardiogram (ultrasound)

Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Robert Hamburger, DO, MPH · University of Florida

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-10-28
Completion
2019-02-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02080390 on ClinicalTrials.gov